المرجو من الزائرين للصفحة دعمنا بالاعجاب و التعليق و المشاركة Les pedimos amablemente a los visitantes de esta página que nos apoyen dándole "me gusta", comentando y compartiendo. We kindly ask visitors to this page to support us by liking, commenting, and sharing. Мы просим посетителей этой страницы поддержать нас, поставив лайк, оставив комментарий и поделившись информацией. 이 페이지를 방문하신 분들께서는 좋아요, 댓글, 공유를 통해 저희를 지원해 주시기 바랍니다. 懇請各位訪客透過按讚、留言和分享來支持我們。 このページの訪問者の皆様には、いいね、コメント、シェアなどでサポートしていただきますようお願いいたします。 हम इस पेज पर आने वाले आगंतुकों से अनुरोध करते हैं कि वे इसे लाइक, कमेंट और शेयर करके हमारा समर्थन करें। Nous demandons gentiment aux visiteurs de cette page de nous soutenir en aimant, commentant et partageant.

Translate

Contact Form

Name

Email *

Message *

Search This Blog

Even if cancer and cardiovascular diseases are considered two distinct diseases, an intricate interconnection between these conditions has been established. Increased risk of malignancy has been identified in patients with cardiovascular disease, as well as a greater propensity to the development of card

 



ABSTRACT


Even if cancer and cardiovascular diseases are considered two distinct diseases, an intricate interconnection between these conditions has been established. Increased risk of malignancy has been identified in patients with cardiovascular disease, as well as a greater propensity to the development of cardiovascular diseases has been observed in patients with cancer. The development of cardiotoxicity following exposure to certain anticancer drugs only partially explains this relationship. Shared risk factors and common pathogenic mechanisms suggest the existence of a common biology and a complex interplay between these two conditions. Due to improving longevity and therapeutic advances, the number of patients affected or potentially at risk of developing these two diseases is constantly increasing and currently, several drugs against cancer from anthracyclines to checkpoint inhibitors, can also cause a wide range of unexpected cardiovascular side effects. Management of these issues in clinical practice is an emerging challenge for cardiologists and oncologists, and led to the development of a new dedicated discipline called cardio-oncology. Surveillance and prevention strategies as well as interventions to reduce cardiovascular risk and prevent cardiotoxicities are the primary objectives of cardio-oncology. In this review, we explore the etiopathogenesis common to cardiovascular disease and cancer and the complex interplay between them. We also report the main characteristics of the drugs responsible for cardiotoxicity, highlighting the available strategies for optimal patient management based on a multidisciplinary approach in the cardio-oncology setting.


PMID:32571000 | DOI:10.4081/monaldi.2020.1348

21:27

In reply to this message

PubMed articles on: Cancer & VTE/PE

Thrombotic Risk in Cancer Patients: Diagnosis and Management of Venous Thromboembolism


Citro R, et al. J Cardiovasc Echogr 2020 - Review.


No comments:

Post a Comment

اكتب تعليق حول الموضوع